Navigation Links
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO

es that regulatory filings to support initiation of this clinical trial will be completed by mid-year 2007. Kosan plans to initiate a larger, international Phase 2/3 trial of alvespimycin in combination with trastuzumab in patients with HER2-positive metastatic breast cancer later in 2007.

Kosan also plans to pursue development of alvespimycin as a treatment for patients with acute myeloid leukemia (AML).

Kosan is also testing alvespimycin delivered orally in a Phase 1 dose escalation trial on both daily and every other day schedules. While dose escalation continues in this trial, early results have shown prolonged stable disease in patients with fibrosarcoma, hemangioendothelioma, melanoma and renal cell carcinoma with a favorable side effect profile.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global devel
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 5, 2011 ORBIS and its global team of ... in Ulaanbaatar, Mongolia (June 19 - July 7) aboard ... hospital with wings. The mission was supported by Alcon ... a three-week ophthalmic skills exchange and surgical program through ...
...   The world-renowned International Journal ... addresses the thermal,aspects of radiofrequency exposure on human health. ... the controversies,surrounding huge growth and use of wireless communication. ... a quantitative,assessment of the effects of thermal energy on ...
Cached Medicine Technology:ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 2ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 3ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 4Is Heat From Radiofrequency Exposure Damaging Human Health? 2Is Heat From Radiofrequency Exposure Damaging Human Health? 3
(Date:4/24/2014)... and stressful outcomes for parents who have a child ... says a recent study led by a researcher at ... numerous and life-changing and stress levels high, the vast ... reported positive outcomes as well, a phenomenon known as ... issue of the American Journal of Orthopsychiatry . ...
(Date:4/24/2014)... in the new Institute for Biomedical Sciences at ... million federal grant to develop novel therapeutics against ... from the Eunice Kennedy Shriver National Institute Of ... Institutes of Health will support Plemper,s drug development ... least one distinct alternative compound. , Infections by ...
(Date:4/24/2014)... give than to receive at least if you,re an ... The study found that 15- and 16-year-olds who find pleasure ... members, are less likely to become depressed than those who ... money for themselves. , The researchers detail their findings in ... , The study focused on the ventral striatum, a brain ...
(Date:4/24/2014)... the influenza pH1N1 virus caused the first flu pandemic ... May 2009 and killed more than 50 people in ... mainly during flu epidemics (winter/spring seasons). , Infections ... complicated illnesses. World Health Organization has recommended Tamiflu for ... disadvantage of this drug is that it targets viral ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... Men and women of all ages are invited to enjoy this 5-day health ... ... Dr. John Spencer,Ellis invites men and women of all ages to enjoy a ... Ellis,welcomes anyone who has completed a fitness program from around the world,as well ...
... boosted pregnancy chances , , THURSDAY, Feb. 7 (HealthDay News) ... chances of becoming pregnant by up to 65 percent ... , , About 10 percent to 15 percent of ... vitro fertilization, in which a woman,s egg is fertilized ...
... ORBIS International is,saddened to announce the death ... of,directors, the Honorable Oliver Foot. He was 61 ... Oliver,s dedication to reduce human suffering caused ... a nonprofit global development,organization that transcends cultural, political ...
... with a certain gene variant drank less and ... the variant while taking the medication naltrexone, according ... Institutes of Health,s 2001-2004 COMBINE (Combined Pharmacotherapies and ... 87 percent of patients with the variant who ...
... CHASE, Md., Feb. 7 This week the,Office ... a statement that "Mr.,Heath Ledger died as the ... oxycodone, hydrocodone, diazepam, temazepam, alprazolam and,doxylamine ...We have ... accident,resulting from the abuse of prescription medications." This ...
... Finding Health and Mental Health Top the List,of Needs, ... series of tornadoes in decades, many people across the ... Cross continues to help,provide meals, shelter and clean up ... welcome help comes from Red Cross health and mental,health ...
Cached Medicine News:Health News:QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravo's The Real Housewives of Orange County 2Health News:Acupuncture May Aid In Vitro Fertilization 2Health News:Acupuncture May Aid In Vitro Fertilization 3Health News:ORBIS International Announces the Death of the Honorable Oliver Foot, President and Board Member 2Health News:Gene variant predicts medication response in patients with alcohol dependence 2Health News:Gene variant predicts medication response in patients with alcohol dependence 3Health News:ASAM Calls for Care in the Use of, and the Prescribing of, Potentially Addictive Substances 2Health News:Tornado-Scarred States Receive American Red Cross Health Services 2Health News:Tornado-Scarred States Receive American Red Cross Health Services 3
... almost all its mechanical strength throughout the ... 915 months. Blunt thread design assists in ... maximize surgeons options. Driver design distributes ... help prevent the screw from breaking or ...
... FDA-cleared third-generation allergy test , 3gAllergy is ... It provides quantitative determination of allergen-specific IgE ... accuracy and lot-to-lot reproducibility. The assay delivers ... help you identify, monitor and manage patients ...
... Screw System is part of a series of ... screws ranging from 3.5 to 8.0 mm. Matching ... the system provides convenience and flexibility for the ... mm system may be customized using two of ...
The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
Medicine Products: